Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Behavioral and Brain Functions
Published in: Behavioral and Brain Functions 1/2005

Open Access 01-12-2005 | Research

Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder

Authors: Amy FT Arnsten, Anne G Dudley

Published in: Behavioral and Brain Functions | Issue 1/2005

Login to get access

Abstract

Background

Methylphenidate (MPH) is the classic treatment for Attention Deficit Hyperactivity Disorder (ADHD), yet the mechanisms underlying its therapeutic actions remain unclear. Recent studies have identified an oral, MPH dose regimen which when given to rats produces drug plasma levels similar to those measured in humans. The current study examined the effects of these low, orally-administered doses of MPH in rats performing a delayed alternation task dependent on prefrontal cortex (PFC), a brain region that is dysfunctional in ADHD, and is highly sensitive to levels of catecholamines. The receptor mechanisms underlying the enhancing effects of MPH were explored by challenging the MPH response with the noradrenergic α2 adrenoceptor antagonist, idazoxan, and the dopamine D1 antagonist, SCH23390.

Results

MPH produced an inverted U dose response whereby moderate doses (1.0–2.0 mg/kg, p.o.) significantly improved delayed alternation performance, while higher doses (2.0–3.0 mg/kg, p.o.) produced perseverative errors in many animals. The enhancing effects of MPH were blocked by co-administration of either the α2 adrenoceptor antagonist, idazoxan, or the dopamine D1 antagonist, SCH23390, in doses that had no effect on their own.

Conclusion

The administration of low, oral doses of MPH to rats has effects on PFC cognitive function similar to those seen in humans and patients with ADHD. The rat can thus be used as a model for examination of neural mechanisms underlying the therapeutic effects of MPH on executive functions in humans. The efficacy of idazoxan and SCH23390 in reversing the beneficial effects of MPH indicate that both noradrenergic α2 adrenoceptor and dopamine D1 receptor stimulation contribute to cognitive-enhancing effects of MPH.
Appendix
Available only for authorised users
Literature
1.
Arnsten AFT, Castellanos FX: Neurobiology of attention regulation and its disorders. Textbook of Child and Adolescent Psychopharmacology. Edited by: Martin A, Scahill L, Charney D and Leckman J. 2002, NY, Oxford Univ. Press, 99-109.
2.
Goldman-Rakic PS: The prefrontal landscape: implications of functional architecture for understanding human mentation and the central executive. Phil Trans R Soc London. 1996, 351: 1445-1453.CrossRef
3.
Robbins TW: Dissociating executive functions of the prefrontal cortex. Phil Trans R Soc London. 1996, 351: 1463-1471.CrossRef
4.
Stuss DT, Knight RT: Principles of Frontal Lobe Function. 2002, New York, Oxford University Press, 616-CrossRef
5.
Barkley RA, Grodzinsky G, DuPaul GJ: Frontal lobe functions in Attention Deficit Disorder with and without Hyperactivity: A review and research report. J Abnormal Child Psych. 1992, 20: 163-188. 10.1007/BF00916547.CrossRef
6.
Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH, Gabrieli JDE: Selective effects of methylphenidate in attention deficit hyperactivity disorder: A functional magnetic resonance study. Proc Nat Acad Sci USA. 1998, 95: 14494-14499. 10.1073/pnas.95.24.14494.PubMedCentralCrossRefPubMed
7.
Mehta AD, Ulbert I, Schroeder CE: Intermodal selective attention in monkeys. I: distribution and timing of effects across visual areas. Cerebral Cortex. 2000, 10: 343-358. 10.1093/cercor/10.4.343.CrossRefPubMed
8.
Solanto MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res. 2002, 130: 65-71. 10.1016/S0166-4328(01)00431-4.CrossRefPubMed
9.
Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ: Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol. 2002, 12: 557-566. 10.1016/S0924-977X(02)00104-9.CrossRefPubMed
10.
Ernst M, Zametkin AJ, Matochik JA, Jons PH, Cohen RM: DOPA decarboxylase activity in attention deficit disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci. 1998, 18: 5901-5907.PubMed
11.
Kuczenski R, Segal DS: Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002, 22: 7264-7271.PubMed
12.
Gerasimov MR, Franceschi M, Volkow ND, Gifford A, Gatley SJ, Marsteller D, Molina PE, Dewey SL: Comparison between intraperitoneal and oral methylphenidate administration: A microdialysis and locomotor activity study. J Pharmacol Exp Ther. 2000, 295: 51-57.PubMed
13.
Gaytan O, Ghelani D, Martin S, Swann AC, Dafny N: Methylphenidate: diurnal effects on locomotor and stereotypic behavior in the rat. Brain Res. 1997, 777: 1-12. 10.1016/S0006-8993(97)00880-9.CrossRefPubMed
14.
McDougall SA, Collins RL, Karper PE, Watson JB, Crawford CA: Effects of repeated methylphenidate treatment in the young rat: sensitization of both locomotor activity and stereotyped sniffing. Exp Clin Psychopharmacol. 1999, 7: 208-218. 10.1037//1064-1297.7.3.208.CrossRefPubMed
15.
Sproson EJ, Chantrey J, Hollis C, Marsden CA, Fone KC: Effect of repeated methylphenidate administration on presynaptic dopamine and behaviour in young adult rats. J Psychopharmacol. 2001, 15: 67-75.CrossRefPubMed
16.
Wultz B, Sagvolden T, Moser EI, Moser MB: The spontaneously hypertensive rat as an animal model of attention-deficit hyperactivity disorder: effects of methylphenidate on exploratory behavior. Behav Neural Biol. 1990, 53: 88-102. 10.1016/0163-1047(90)90848-Z.CrossRefPubMed
17.
Amini B, Yang PB, Swann AC, Dafny N: Differential locomotor responses in male rats from three strains to acute methylphenidate. Int J Neurosci. 2004, 114: 1063-1084. 10.1080/00207450490475526.CrossRefPubMed
18.
Kuczenski R, Segal DS: Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther. 2001, 296: 876-883.PubMed
19.
Berridge CW, Stalnaker TA: Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex. Synapse. 2002, 46: 140-149. 10.1002/syn.10131.CrossRefPubMed
20.
Arnsten AFT, Robbins TW: Neurochemical modulation of prefrontal cortical function in humans and animals. Principles of Frontal Lobe Function. Edited by: Stuss DT and Knight RT. 2002, New York, Oxford University Press, 51-84.CrossRef
21.
Arnsten AFT, Li BM: Neurobiology of executive functions: Catecholamine influences on prefrontal cortical function. Biological Psychiatry. 2005, in press:
22.
Arnsten AFT: Stress impairs PFC function in rats and monkeys: Role of dopamine D1 and norepinephrine alpha-1 receptor mechanisms. Prog Brain Res. 2000, 126: 183-192.CrossRefPubMed
23.
Larsen JK, Divac I: Selective ablations within the prefrontal cortex of the rat and performance of delayed alternation. Physiolog Psychol. 1978, 6: 15-17.CrossRef
24.
Mishkin M: Perseveration of central sets after frontal lesions in monkeys. The Frontal Granular Cortex and Behavior. Edited by: Warren JM and Akert K. 1964, New York, McGraw-Hill, 219-241.
25.
Butter CM: Perseveration in extinction and in discrimination reversal following selective frontal ablations in Macaca mulatta. Physiol Behav. 1968, 4: 163-171. 10.1016/0031-9384(69)90075-4.CrossRef
26.
Collins P, Roberts AC, Dias R, Everitt BJ, Robbins TW: Perseveration and strategy in a novel spatial self-ordered sequencing task for nonhuman primates: effects of excitotoxic lesions and dopamine depletions of the prefrontal cortex. J Cognitive Neuroscience. 1998, 10: 332-354. 10.1162/089892998562771.CrossRef
27.
Zahrt J, Taylor JR, Mathew RG, Arnsten AFT: Supranormal stimulation of dopamine D1 receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997, 17: 8528-8535.PubMed
28.
Arnsten AFT, Mathew R, Ubriani R, Taylor JR, Li BM: Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry. 1999, 45: 26-31. 10.1016/S0006-3223(98)00296-0.CrossRefPubMed
29.
Birnbaum SG, Gobeske KT, Auerbach J, Taylor JR, Arnsten AFT: A role for norepinephrine in stress-induced cognitive deficits: Alpha-1-adrenoceptor mediation in prefrontal cortex. Biol Psychiatry. 1999, 46: 1266-1274. 10.1016/S0006-3223(99)00138-9.CrossRefPubMed
30.
Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW: Effects of methylphenidate on spatial working memory and planning in healthy young adults. Psychopharmacology. 1997, 131: 196-206. 10.1007/s002130050284.CrossRefPubMed
31.
Trommer BL, Hoeppner JA, Zecker SG: The go-no go test in attention deficit disorder is sensitive to methylphenidate. J Child Neurol. 1991, 6 Suppl: S128-31.PubMed
32.
Bedard AC, Ickowicz A, Logan GD, Hogg-Johnson S, Schachar R, Tannock R: Selective inhibition in children with attention-deficit hyperactivity disorder off and on stimulant medication. J Abnorm Child Psychol. 2003, 31: 315-327. 10.1023/A:1023285614844.CrossRefPubMed
33.
Aron AR, Dowson JH, Sahakian BJ, Robbins TW: Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2003, 54: 1465-1468. 10.1016/S0006-3223(03)00609-7.CrossRefPubMed
34.
Mehta MA, Goodyer IM, Sahakian BJ: Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. J Child Psychol Psychiatry. 2004, 45: 293-305. 10.1111/j.1469-7610.2004.00221.x.CrossRefPubMed
35.
Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ: Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology. 2004, epub:
36.
Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW: Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neuroscience. 2000, 20: RC651-656.
37.
Robbins TW, Sahakian BJ: "Paradoxical" effects of psychomotor stimulant drugs in hyperactive children from the standpoint of behavioral pharmacology. Neuropharmacol. 1979, 18: 931-950. 10.1016/0028-3908(79)90157-6.CrossRef
38.
Solanto MV, Wender EH: Does methylphenidate constrict cognitive functioning?. J Am Acad Child Adolesc Psychiatry. 1989, 28: 897-902.CrossRefPubMed
39.
Dyme IZ, Sahakian BJ, Golinko BE, Rabe EF: Perseveration induced by methylphenidate in children: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry. 1982, 6: 269-273.CrossRefPubMed
40.
Tannock R, Schachar R: Methylphenidate and cognitive perseveration in hyperactive children. J Child Psychol Psychiatry. 1992, 33: 1217-1228.CrossRefPubMed
41.
Douglas VI, Barr RG, Desilets J, Sherman E: Do high doses of stimulants impair flexible thinking in attention-deficit hyperactivity disorder?. J Am Acad Child Adolesc Psychiatry. 1995, 34: 877-885. 10.1097/00004583-199507000-00011.CrossRefPubMed
42.
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002, 27: 699-711. 10.1016/S0893-133X(02)00346-9.CrossRefPubMed
43.
Brozoski T, Brown RM, Rosvold HE, Goldman PS: Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979, 205: 929-931.CrossRefPubMed
44.
Sawaguchi T, Goldman-Rakic PS: The role of D1-dopamine receptors in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed response task. J Neurophysiol. 1994, 71: 515-528.PubMed
45.
Sawaguchi T, Goldman-Rakic PS: D1 dopamine receptors in prefrontal cortex: Involvement in working memory. Science. 1991, 251: 947-950.CrossRefPubMed
46.
Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW: Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci. 2000, 20: 1208-1215.PubMed
47.
Biederman J, Spencer T: Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry. 1999, 46: 1234-1242. 10.1016/S0006-3223(99)00192-4.CrossRefPubMed
48.
Biederman J, Spencer TJ: Genetics of childhood disorders: XIX. ADHD, Part 3: Is ADHD a noradrenergic disorder?. J Am Acad Child Adolesc Psychiatry. 2000, 39: 1330-1333. 10.1097/00004583-200010000-00024.CrossRefPubMed
49.
50.
Kuczenski R, Segal DS: Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem. 1997, 68: 2032-2037.CrossRefPubMed
51.
Ma CL, Arnsten AFT, Li BM: Locomotor hyperactivity induced by blockade of prefrontal cortical alpha-2-adrenoceptors in monkeys. Biological Psychiatry. 2005, in press:
52.
Ma CL, Qi XL, Peng JY, Li BM: Selective deficit in no-go performance induced by blockade of prefrontal cortical alpha2-adrenoceptors in monkeys. Neuroreport. 2003, 14: 1013-1016. 10.1097/00001756-200305230-00021.PubMed
53.
Li BM, Mei ZT: Delayed response deficit induced by local injection of the alpha-2 adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol. 1994, 62: 134-139.CrossRefPubMed
54.
Li BM, Mao ZM, Wang M, Mei ZT: Alpha-2 adrenergic modulation of prefrontal cortical neuronal activity related to spatial working memory in monkeys. Neuropsychopharmacol. 1999, 21: 601-610. 10.1016/S0893-133X(99)00070-6.CrossRef
55.
Arnsten AFT, Cai JX, Goldman-Rakic PS: The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J Neurosci. 1988, 8: 4287-4298.PubMed
56.
Mao ZM, Arnsten AFT, Li BM: Local infusion of alpha-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry. 1999, 46: 1259-1265. 10.1016/S0006-3223(99)00139-0.CrossRefPubMed
57.
Arnsten AFT, Contant TA: Alpha-2 adrenergic agonists decrease distractability in aged monkeys performing a delayed response task. Psychopharmacology. 1992, 108: 159-169.CrossRefPubMed
58.
Steere JC, Arnsten AFT: The alpha-2A noradrenergic agonist, guanfacine, improves visual object discrimination reversal performance in rhesus monkeys. Behav Neurosci. 1997, 111: 1-9.CrossRef
59.
Wang M, Ji JZ, Li BM: The alpha(2A)-adrenergic agonist guanfacine improves visuomotor associative learning in monkeys. Neuropsychopharmacology. 2004, 29: 86-92. 10.1038/sj.npp.1300278.CrossRefPubMed
60.
Wang M, Tang ZX, Li BM: Enhanced visuomotor associative learning following stimulation of alpha 2A-adrenoceptors in the ventral prefrontal cortex in monkeys. Brain Res. 2004, 1024: 176-182. 10.1016/j.brainres.2004.07.062.CrossRefPubMed
61.
Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AFT: The alpha-2A-adenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000, 23: 240-249. 10.1016/S0893-133X(00)00111-1.CrossRefPubMed
62.
Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002, 63: 1140-1147.CrossRefPubMed
63.
Scahill L, Chappell PB, Kim YS, Schultz RT, Katsovich L, Shepherd E, Arnsten AFT, Cohen DJ, Leckman JF: Guanfacine in the treatment of children with tic disorders and ADHD: A placebo-controlled study. Amer J Psychiatry. 2001, 158: 1067-1074. 10.1176/appi.ajp.158.7.1067.CrossRef
64.
Franowicz JS, Kessler L, Dailey-Borja CM, Kobilka BK, Limbird LE, Arnsten AFT: Mutation of the alpha2A-adrenoceptor impairs working memory performance and annuls cognitive enhancement by guanfacine. J Neurosci. 2002, 22: 8771-8777.PubMed
65.
Tanila H, Rama P, Carlson S: The effects of prefrontal intracortical microinjections of an alpha-2 agonist, alpha-2 antagonist and lidocaine on the delayed alternation performance of aged rats. Brain Res Bull. 1996, 40: 117-119. 10.1016/0361-9230(96)00026-3.CrossRefPubMed
66.
Rama P, Linnankoski I, Tanila H, Pertovaara A, Carlson S: Medetomidine, atipamezole, and guanfacine in delayed response performance of aged monkeys. Pharmacol Biochem Behav. 1996, 54: 1-7. 10.1016/S0091-3057(96)90003-9.CrossRef
67.
Jakala P, Riekkinen M, Sirvio J, Koivisto E, Kejonen K, Vanhanen M, Riekkinen PJ: Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 1999, 20: 460-470. 10.1016/S0893-133X(98)00127-4.CrossRefPubMed
Metadata
Title
Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder
Authors
Amy FT Arnsten
Anne G Dudley
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Behavioral and Brain Functions / Issue 1/2005
Electronic ISSN: 1744-9081
DOI
https://doi.org/10.1186/1744-9081-1-2

Other articles of this Issue 1/2005

Behavioral and Brain Functions 1/2005 Go to the issue

Short paper

Branching projections of ventrolateral reticular neurons to the medial preoptic area and lumbo-sacral spinal cord

Research

Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strains

Research

Association study of polymorphisms in synaptic vesicle-associated genes, SYN2 and CPLX2, with schizophrenia

Research

Response inhibition deficits in externalizing child psychiatric disorders: An ERP-study with the Stop-task

Research

Induction of compulsive-like washing by blocking the feeling of knowing: an experimental test of the security-motivation hypothesis of Obsessive-Compulsive Disorder

Research

Efficacy of atomoxetine in adult attention-Deficit/Hyperactivity Disorder: a drug-placebo response curve analysis